Basic Daxas Information

• INN (International Nonproprietary Name): Metformin
• Brand Names Available In United Kingdom: Glucophage, Siofor, Metforal
• ATC Code: A10BA02
• Forms & Dosages: Immediate-release tablets 250mg, 500mg, 850mg, 1000mg; extended-release tablets 500mg, 750mg, 1000mg; oral solution 500mg/5mL
• Manufacturers In United Kingdom: not specified
• Registration Status In United Kingdom: not specified
• OTC / Rx Classification: Prescription Only (Rx)

Important Instructions, Warnings And Daily-Life Integration For UK Patients

If you have sudden mood change, suicidal thoughts, unexplained weight loss or severe diarrhoea, contact NHS 111 or your GP urgently.

For emergencies call 999.

Daxas (roflumilast 500 micrograms tablets) is prescription-only in the UK (MHRA).

For context, many chronic medicines are prescription-only, so expect a GP or respiratory specialist prescription and pharmacy dispensing.

A practical way to stay on top of treatment is to take Daxas at the same time each evening to aid adherence.

Carry an NHS repeat prescriptions list so the pharmacist and clinician can see current treatments quickly.

Keep a simple symptom diary noting exacerbations, mood, weight and sleep to help reviews with your COPD nurse or GP.

Before driving or operating machinery, watch for dizziness, sleep disturbance or mood changes and avoid these activities if affected.

Do not stop other COPD inhalers unless told to do so by your prescriber.

Preferable practical aids include a checklist and a wallet-sized summary card showing medicine name, dose, prescriber and emergency actions.

Morning Vs Evening Dosing

Many patients prefer to take Daxas 500 micrograms once daily in the evening, commonly after dinner, to reduce noticeability of mild gastrointestinal effects and to fit routine.

Evening dosing is often recommended because side effects such as insomnia or dizziness may be less disruptive when you sleep.

If evening dosing causes sleep problems, discuss switching times with your prescriber rather than changing the dose yourself.

Taking With Or Without Meals (UK Diet Habits)

Daxas can be taken with or without food according to product guidance.

If you have a hearty evening meal, taking Daxas right after eating may reduce stomach upset.

Typical British dinners—such as a roast or pasta—can help buffer mild nausea for the first few weeks of therapy.

Practical Advice For Everyday Use

Aim to take Daxas 500 micrograms once daily, usually in the evening as advised by your clinician.

If you forget a dose, take it when you remember unless it is close to the next dose; do not double dose.

Link the tablet to an existing habit such as toothbrushing or settling down to bed to make it easier to remember.

Use a daily pill box or the NHS Repeat Prescription online service to order repeats reliably.

• Adherence Tips: Keep a visible medication reminder, set a phone alarm for your evening dose and review repeat prescriptions monthly.
• Printable Checklist: Evening routine: take Daxas, note weight, record any nausea or mood change, check inhaler use.

Everyday Use & Best Practices

Morning Vs Evening Dosing

Many clinicians advise evening dosing of roflumilast because it tends to make daytime side effects less noticeable.

If insomnia or vivid dreams occur with evening dosing, a prescriber may consider a different timing strategy.

Taking With Or Without Meals (UK Diet Habits)

There is no strict food restriction for Daxas, so you can usually take it with or without food.

For patients who eat a substantial evening meal, taking Daxas immediately after food can often ease nausea or stomach discomfort.

Practical Advice For Everyday Use

Start by setting a consistent evening time for your tablet and link it to an established nightly routine.

Keep a small symptom diary to record exacerbations, GI effects and mood changes to share at reviews.

• Use the NHS Repeat Prescription online service or your community pharmacy to avoid missed supplies.
• Consider a weekly check-in with a partner, carer or friend to notice early mood changes.
• Photocopy a wallet-sized summary card showing: Daxas, roflumilast 500 micrograms, prescriber contact and urgent actions.

Safety Priorities

Who Should Avoid It (MHRA Warnings)

Do not take Daxas if you have severe hepatic impairment; product guidance advises against use in severe liver disease.

Tell your GP about any history of severe depression, suicidal ideation, significant unintentional weight loss or marked undernutrition before starting.

Roflumilast has been associated with psychiatric adverse events including depression, anxiety and suicidal thoughts, so baseline and ongoing assessment of mood is important.

Activities To Limit (Driving, Work Safety)

Avoid driving or operating heavy machinery until you know how Daxas affects you.

If you experience dizziness, tremor or severe sleep disturbance, stop driving and inform your clinician promptly.

For safety-critical jobs, discuss risks with occupational health and your prescriber before starting treatment.

Who Should Avoid Daxas And What To Limit

Patients with severe liver disease should not use Daxas.

Alcohol intake should be limited because it may worsen gastrointestinal or psychiatric side effects.

During acute respiratory infection or perioperative periods, follow GP or surgical advice; temporary pauses in roflumilast may be recommended.

• Contraindications Checklist: Severe hepatic impairment, current severe depression or suicidal ideation, significant recent weight loss.
• Mood Monitoring: Check mood weekly for the first months and involve a family member or carer if possible.

Dosage & Adjustments

General Regimen (NHS Guidance)

The standard prescribed dose of Daxas is roflumilast 500 micrograms once daily.

Confirm the exact wording on your prescription and ensure the tablet strength is 500 micrograms.

There is normally no slow titration and most patients start on the standard dose unless a specialist advises otherwise.

Special Cases (Elderly, Comorbidities)

Older adults may be more sensitive to weight loss, dizziness and psychiatric effects, and usually require closer monitoring.

In moderate hepatic impairment dose adjustment or alternative therapy should be discussed with a prescriber; Daxas is not recommended in severe hepatic impairment.

Renal impairment typically does not require routine adjustment, but frail patients should be reviewed clinically.

Typical Dosing And How It’s Tailored

If a dose is missed, take it when remembered unless it is near the next scheduled dose; never double up to catch up.

Clinicians will usually monitor weight, mood and liver function during early treatment and at regular intervals thereafter.

• Elderly Monitoring Checklist: Baseline weight, monthly weight checks in the first three months, mood screening and LFTs as advised.
• Hepatic Impairment: Not recommended in severe impairment; discuss options if liver disease is present.

User Testimonials

Positive Reports From UK Patients

Many UK patients with chronic bronchitic COPD report fewer exacerbations and fewer courses of steroids or antibiotics after starting roflumilast.

Patients commonly say they can plan social activities better because flare-ups are less frequent.

Common Challenges (Patient.info, NHS Forums)

Gastrointestinal upset such as nausea and diarrhoea, weight loss and sleep disturbance are commonly mentioned on forums like Patient.info and NHS-connected discussion boards.

Some patients stop treatment within weeks because of these effects, and a minority describe mood changes, which are emphasised in regulatory guidance.

Real-World Patient Experiences

Starting Daxas with a firm evening routine and a light meal beforehand helps some patients persevere through transient GI effects.

Regular weigh-ins and prompt communication with COPD nurses or pharmacists are frequent practical coping strategies reported by users.

• Positive Outcomes: Fewer hospital admissions for exacerbations, more stable day-to-day activity, reduced steroid exposure.
• Common Challenges: Nausea, diarrhoea, weight loss and occasional mood changes.

Bring a short patient checklist to appointments to help prescribers tailor monitoring and support.

Buying Guide

Pharmacy Sources (Boots, LloydsPharmacy, Superdrug)

Daxas requires a prescription from your GP or respiratory specialist in the UK and can be collected from community pharmacies such as Boots, LloydsPharmacy, Superdrug or NHS Trust pharmacies.

Hospital outpatient pharmacies may supply the first prescription after clinic review.

Price Comparison (NHS Prescription Charge Vs Private)

If eligible you will get Daxas under NHS prescription rules where prescriptions are subsidised or free depending on nation and exemption status.

Remember that England applies a standard prescription charge for most single items unless you are exempt, while Scotland, Wales and Northern Ireland generally provide free prescriptions for residents.

Some online UK-registered pharmacies will dispense Daxas with an NHS or private prescription; always check the pharmacy is registered with the MHRA.

Our online pharmacy offers discrete delivery across the United Kingdom and lists daxas without a prescription for convenience, with delivery times stated below.

Where To Get Daxas And Cost Considerations

Consider Prescription Prepayment Certificates in England if you take several prescription medicines to reduce overall cost.

Hospital COPD clinics sometimes supply short-term samples when treatment is being initiated and assessed for tolerability.

• Collection Points: Community pharmacy, hospital outpatient pharmacy, registered online pharmacy with a valid prescription.
• Cost-Saving Options: NHS repeat prescriptions, prepayment certificates and pharmacy-managed repeat ordering.

What’s Inside & How It Works

Ingredients Overview

The active ingredient in Daxas is roflumilast 500 micrograms per tablet.

Inactive ingredients vary by manufacturer, so check the patient leaflet for known allergens or sensitivities.

Mechanism Basics Explained Simply

Roflumilast is a PDE4 inhibitor that reduces inflammation in the lungs by blocking the enzyme PDE4 involved in inflammatory cell signalling.

That reduction in lung inflammation helps lower the frequency of COPD exacerbations, particularly in patients with chronic bronchitis and frequent flare-ups.

Daxas is an oral anti-inflammatory that complements inhaled bronchodilators and does not replace inhalers such as LABA/LAMA combinations or inhaled corticosteroids when these are indicated.

Store Daxas in the original packaging, keep it dry and below the recommended temperature and follow storage advice similar to many prescription medicines.

Main Indications

Approved Uses (MHRA Listing)

Daxas is licensed to reduce the risk of exacerbations in adult patients with severe COPD associated with chronic bronchitis and a history of frequent exacerbations despite regular bronchodilator therapy.

This aligns with MHRA authorisation and specialist prescribing practice in the UK.

Off-Label Uses In UK Clinics

Some clinicians may consider roflumilast for particular inflammatory phenotypes as part of a multi-disciplinary COPD optimisation plan, but this should be documented and discussed with the patient.

Treatment is usually long term if benefit is seen, and regular review for side effects and effectiveness is standard practice.

• Eligibility Checklist: Chronic productive cough, frequent exacerbations requiring steroids or antibiotics, disease optimised on inhaled therapy.
• Review Points: Assess exacerbation frequency, weight changes and mood at each review.

Interaction Warnings

Food Interactions (Alcohol, Tea/Coffee)

There are no major food interactions listed for Daxas, but heavy alcohol intake should be avoided as it may worsen psychiatric and gastrointestinal side effects.

Caffeinated drinks are not contraindicated, but discuss consumption with your clinician if insomnia develops.

Drug Conflicts (MHRA Yellow Card Reports)

Roflumilast is metabolised by CYP enzymes, mainly CYP3A4 and CYP1A2, so interactions with strong inducers or inhibitors of these enzymes can alter drug levels.

Strong CYP3A4 inducers such as rifampicin, carbamazepine or phenobarbital can reduce roflumilast exposure and effectiveness.

Strong inhibitors may increase exposure and potential side effects; always tell your pharmacist about all medicines, herbal remedies and over-the-counter products.

Report suspected adverse reactions such as psychiatric effects or marked weight loss via the MHRA Yellow Card scheme.

Latest Evidence & Insights

Key UK & EU Studies 2022–2025

Recent trials and reviews continue to support roflumilast’s role in reducing moderate-to-severe exacerbations in chronic bronchitic COPD phenotypes.

UK and EU respiratory guideline updates emphasise careful patient selection to maximise benefit and reduce discontinuation due to side effects.

Real-world registry data show a modest absolute reduction in exacerbation rates for selected patients, balanced against higher rates of gastrointestinal and neuropsychiatric events.

Practical Takeaways For Patients

If selected for Daxas expect an initial trial period with active monitoring of weight, mood and exacerbation frequency.

Benefits often become apparent over months rather than weeks, and lack of benefit or intolerable side effects should prompt reassessment with your clinician.

• Ask your COPD clinic about local audit data or outcomes so you can see how patients in your area fare on roflumilast.
• Maintain a simple exacerbation log to demonstrate any change in flare-up frequency during treatment.

Alternative Choices

NHS Prescribing Alternatives With Pros/Cons Checklist

Alternatives used on the NHS for exacerbation prevention include optimising inhaled therapy, pulmonary rehabilitation and, in selected patients, long-term macrolide therapy.

Vaccinations against influenza and pneumococcus remain important and reduce exacerbation risk indirectly.

When To Discuss Stepping Down Or Switching

If you experience significant weight loss greater than 5 per cent of bodyweight, new or worsening depression or no reduction in exacerbations after an agreed trial period, discuss stepping down with your clinician.

A shared decision should consider symptom control, side effects and quality of life.

Regulation Snapshot

MHRA Approval & Monitoring

Daxas is MHRA-approved for specified COPD indications and the product information highlights psychiatric events and hepatic impairment as key warnings.

Clinicians report adverse events via the Yellow Card scheme to aid ongoing safety monitoring.

NHS Prescribing Framework

Daxas is generally initiated by respiratory specialists and may be continued in primary care under shared-care agreements with clear monitoring responsibilities.

Trust formularies or local Health Board policies can restrict prescribing to patients who meet defined eligibility criteria.

• Check local CCG/ICS or Health Board guidance for specific prescribing pathways and monitoring responsibilities.

FAQ Section

Can I Stop It If I Feel Worse?

If you develop severe mood changes, suicidal thoughts, marked weight loss or intolerable side effects, stop and seek urgent medical review.

For milder effects contact your GP or COPD nurse first; they may advise supportive measures or reassessment rather than immediate cessation.

Will It Affect My Driving Or Work?

Daxas can affect driving or operation of machinery if it causes dizziness, drowsiness, confusion or severe sleep disturbance.

For safety-critical employment, speak to occupational health and your clinician before starting treatment.

How Long Before I See Benefit?

Reduction in exacerbations is usually assessed over months, with many patients and clinicians evaluating benefit over three to six months.

If no clear benefit is seen after an agreed trial, discuss stopping or switching options with your prescriber.

Where To Get More Information?

Consult the patient information leaflet, NHS.uk COPD pages and your local respiratory clinic for tailored advice.

Guidelines For Proper Use

UK Pharmacist Counselling Style

Pharmacists should confirm the prescribed dose of roflumilast 500 micrograms once daily and explain likely side effects such as GI upset, weight loss and mood changes.

They should advise evening dosing, explain when to seek urgent help and review other medicines for interactions.

NHS Patient Support Advice

Register for regular COPD review appointments and bring a symptom and exacerbation log to help clinicians assess benefit.

Request weight checks and mood screening at reviews and ensure vaccines are up to date.

What To Ask Your Clinician

Ask: “Am I eligible for Daxas?”, “What monitoring will you do?”, “Who do I call about mood changes?” and “When will we review effectiveness?”.

• Pharmacist Counselling Checklist: Confirm dose, advise evening intake, flag urgent symptoms and provide written leaflet and monitoring checklist.
• Patient Monitoring Diary Template: Date, dose taken, weight, mood rating, any GI symptoms, any exacerbations and medication use.

Delivery Across United Kingdom